IDH1 and acute myeloid leukemia: With median follow-up of 8.3 months for 174 adults with IDH1-mutated relapsed/refractory (R/R) AML treated with 500 mg ivosidenib daily, the CR + CRh rate was 33% [95% confidence interval (CI), 26-40], median duration of response was 8.2 (95% CI, 5.6-12) months, and conversion from TD to TI occurred in 37% of patients (38).